By engaging multiple steps of the anti-tumor immune response, dual blockade may overcome intrinsic tumor heterogeneity, low PD-L1 expression, and immunosuppressive microenvironments, thus producing efficacy across histologic, molecular, and CNS-involved subgroups. Here, CD274 is linked to neoplasm.